MedTrace Logo

Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer

NCT03846128 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2026-04-14

No results posted yet for this study

Summary

Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney cancer.

Collection of additional blood tubes during routine blood tests for patient follow-up, to evaluate the plasma concentration of Sunitinib and its active metabolite desethyl-Sunitinib (DES)

Conditions

  • Metastatic Kidney Cancer

Interventions

BIOLOGICAL

blood sample

blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1

Sponsors & Collaborators

  • University Hospital, Rouen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-03
Primary Completion
2021-10-08
Completion
2021-10-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03846128 on ClinicalTrials.gov